Is Your Paper Ready for JCO? Practice-Changing Oncology Only

Definitive Phase 3 randomized controlled trials. Large, multicenter, adequately powered trials comparing a new treatment to the established standard of care. The core currency is the primary analysis of a completed Phase 3 trial with mature survival data. Interim analyses and post-hoc subgroup findings occasionally appear, but they aren't the norm.

Landmark Phase 2 trials for rare cancers. A well-designed single-arm Phase 2 in a cancer affecting a few hundred patients per year can be practice-changing if response rates are dramatic enough. You need to show that randomization wasn't realistic and that the treatment effect eliminates equipoise.

Health services research. JCO publishes a steady stream of papers on healthcare delivery, outcomes disparities, survivorship, and healthcare economics, anything that addresses how oncology care is delivered, not just what treatments work.

Guideline-informing meta-analyses. These need to resolve genuine clinical uncertainty. A meta-analysis confirming what everyone already knows won't survive desk review. One that settles whether adjuvant therapy benefits a specific molecular subtype will.

Note on article types: Beyond Original Reports (~13% acceptance), JCO also publishes Brief Reports, Reviews, Editorials, and Special Articles. Brief Reports follow similar standards but with tighter word limits. The $80 submission fee applies only to Original Reports and Brief Reports. Other article types, including editorials and invited reviews, have no submission fee.

About one-third of submissions never reach external review. With only ~342 articles published per year and thousands of submissions, the editors are aggressive at the desk. Common triggers:

• Phase 1 and dose-finding studies. Dose-escalation data without clinical endpoints belongs in specialty journals. Unless you've found an extraordinary signal in a previously untreatable cancer, pharmacokinetics alone won't pass.
• Phase 2 trials for common cancers. If enough patients exist for Phase 3, JCO expects randomization. A single-arm Phase 2 in NSCLC or breast cancer won't pass the desk. There's no rarity argument to justify absent randomization.
• Biomarker discovery without clinical validation. JCO wants prospective validation or a convincing independent retrospective cohort. "We found an association" belongs in Clinical Cancer Research or Cancer Research.
• Translational biology with a thin clinical wrapper. If the core contribution is mechanistic, the paper belongs at Cancer Cell, Cancer Discovery, or Nature Cancer. Adding a paragraph about how findings "might eventually influence treatment" doesn't fool the editors.
• Surgical technique papers. JCO publishes surgical oncology only when the question is about patient outcomes, not surgical methods. A new laparoscopic approach that reduces OR time won't make it. A randomized trial showing a surgical strategy improves overall survival will.

ASCO journals use EZSubmit, a format-free policy. You don't need to match JCO's style before the first decision. What you do need:

• Cover letter explaining clinical significance
• Title page with all author information
• Structured abstract
• Complete reference list (any standard format)
• CONSORT flow diagram (required for randomized studies)
• Trial protocol (required for randomized/interventional trials)

The $80 nonrefundable fee for Original Reports is charged at submission. ASCO also requires that new submissions do not exceed the article type's word limit by more than 1,000 words.

Choose JCO when your trial will directly change ASCO or NCCN guidelines. The ASCO affiliation means your paper gets discussed at ASCO meetings and referenced in guidelines faster than if it appeared elsewhere.

Choose Lancet Oncology when your trial has a strong international or global health dimension. Lancet's editorial commentaries can amplify impact, but you'll need Lancet-specific formatting from first submission.

Choose JAMA Oncology when your paper sits at the intersection of clinical oncology and population health or healthcare policy. Lower IF, but strong readership among policymakers.

A common cascade: submit to JCO first, then Lancet Oncology, then JAMA Oncology. EZSubmit at JCO and JAMA makes this painless in formatting terms.

For randomized studies, CONSORT compliance isn't optional. JCO requires the full flow diagram showing enrollment, randomization, follow-up, and analysis. Reviewers check whether your ITT population matches the diagram and whether loss-to-follow-up raises bias concerns.

For randomized and interventional trials, you must also submit the trial protocol. Reviewers compare it against the paper, looking for outcome switching, unregistered subgroup analyses, and deviations from the pre-specified statistical plan.

Common failure: a CONSORT diagram where items say "see Methods section" instead of giving actual numbers. Reviewers read that as sloppy trial reporting, and it can sink an otherwise strong paper.

Papers that survive the desk get assigned to an Associate Editor and typically two to three external reviewers. The turnaround is fast by clinical journal standards, about four weeks from assignment to decision. JCO's editors know that clinical trial results age poorly. Competing trials report, treatment landscapes shift, and new standards of care emerge.

First-round decisions tend to be decisive. You'll get accept with minor revisions (rare), major revisions with a clear path to acceptance, or reject after review. The ambiguous "revise and resubmit with no guarantee" outcome is less common at JCO. The editors usually know by the time reviews come back whether the paper will make it.

Revision requests focus on sensitivity analyses, subgroup effects, comparison to recently reported trials, and clinical applicability. Reviewers are less likely to request new experiments (your trial is done) and more likely to ask for additional statistical analyses, longer follow-up data if available, or clearer discussion of how the findings should change practice.

Don't summarize the paper, editors will read the abstract. Instead, answer three questions:

1. What clinical question does this paper answer?
2. What is the current standard of care, and how will your findings change it?
3. Which specific guidelines should be updated based on your results?

If you can't answer the third question with a specific guideline citation, JCO probably isn't the right target. Being vague about "potential impact on clinical practice" signals that the practice change isn't clear enough for JCO's scope.

A JCO manuscript fit check at this stage can identify scope mismatches and common structural issues before you finalize your submission.

Before submitting, ask yourself these questions without hedging:

Will treatment guidelines change based on your results? Not "might they eventually contribute to a guideline change." Will they change? If you've completed a definitive Phase 3 trial that answers a question the NCCN guidelines panel is waiting on, the answer is yes. If your result is one data point among several that might collectively shift opinion, JCO may not be your first choice.

Is your trial design defensible to practicing oncologists? JCO's reviewers are clinicians. They evaluate eligibility criteria, treatment protocols, and endpoints through the lens of clinical practice, not just statistical rigor.

Have you presented at ASCO or another major meeting? Not a requirement, but JCO papers frequently originate from ASCO plenary or oral sessions. If your trial wasn't selected for a major meeting presentation, it may not meet JCO's threshold.

Can you state who should be treated differently? "Oncologists treating patients with stage III MSS colorectal cancer should now consider adding agent X to standard FOLFOX" is the kind of statement JCO papers support. If you can't write that sentence, the paper may lack the clinical specificity JCO demands.

A JCO submission readiness check can evaluate whether your manuscript's framing communicates the practice-changing significance that JCO editors screen for during desk review.

In our pre-submission review work with manuscripts targeting the Journal of Clinical Oncology, five patterns generate the most consistent desk rejections worth knowing before submission.

The trial that doesn't change guidelines.

According to JCO's author guidelines, the journal prioritizes clinical research findings that would alter oncology practice or clinical guidelines; Phase 2 trials and observational studies that confirm established patterns without providing definitive evidence for practice change face desk rejection. We see this pattern in manuscripts we review more frequently than any other JCO-specific failure. Papers reporting Phase 2 efficacy data, or retrospective analyses demonstrating associations already established in the literature, do not clear the guideline-relevance filter. In our experience, roughly 35% of manuscripts we review targeting JCO are trials or observational studies where the primary contribution is hypothesis-generating rather than practice-defining.

The trial with incomplete CONSORT or SPIRIT reporting.

Per JCO's reporting standards, all randomized controlled trials must include a completed CONSORT checklist and all prospective trial protocols must include SPIRIT reporting; missing or partially completed checklists are identified during submission processing and returned. We see this in roughly 25% of manuscripts we review for JCO, where CONSORT checklists have multiple items marked as not applicable without justification, or where protocol reporting lacks pre-specified endpoints. Editors consistently return papers where required reporting standards have not been met before scientific evaluation.

The basic science paper without direct clinical translation.

According to JCO's scope, the journal publishes clinical investigation and does not publish laboratory science without direct translational relevance; papers reporting mechanistic findings in cell lines or animal models without patient data or clinical context face scope rejection. In our experience, roughly 20% of manuscripts we review for JCO are laboratory oncology studies that lack the clinical component JCO's oncologist readership expects. Editors consistently screen for papers where the primary evidence comes from patients rather than preclinical systems.

The surrogate endpoint trial without survival data.

Per JCO's evidence standards, trials reporting surrogate endpoints such as response rate or progression-free survival without connecting findings to overall survival or patient-reported outcomes face harder scrutiny at review. We see this in roughly 15% of manuscripts we review for JCO, where trials achieve their primary endpoint on a surrogate measure but do not demonstrate or discuss implications for survival outcomes. Editors consistently flag papers where the clinical meaningfulness of the endpoint is not established.

The statistical analysis that overstates exploratory findings.

According to JCO's statistical reporting expectations, exploratory and post-hoc analyses must be clearly labeled as hypothesis-generating rather than confirmatory. We see this in roughly 10% of manuscripts we review for JCO, where subgroup analyses or secondary endpoints are presented with the same confidence as pre-specified primary outcomes. Editors consistently flag papers where confirmatory language is used for exploratory statistics without appropriate qualification.

SciRev author-reported data for JCO confirms approximately 4 weeks median to first decision after external review assignment, consistent with the fast review cycle the journal maintains for time-sensitive clinical trial results. Before submitting to the Journal of Clinical Oncology, a JCO manuscript fit check identifies whether the trial design, reporting standards, and clinical significance meet JCO's editorial bar before you commit to the submission.

Ready to submit if:

• You can pass every item on the checklist above without qualifying language
• An experienced colleague in your field has read the manuscript and agrees it's competitive
• The data package is complete, no pending experiments or analyses
• You have identified why JCO specifically (not just prestige) is the right venue

Not ready yet if:

• You skipped checklist items because you "plan to add them later"
• The methods section still has draft or incomplete protocol text
• Key figures are drafts rather than publication-quality
• You cannot articulate what distinguishes this paper from recent JCO publications